Skip to main content

Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

Completed · Not applicable · NCT04795752

Conditions: Dry Eye, Meibomian Gland Dysfunction

At a glance

Research payments reported, 2025
$219,026
U.S. investigators named
16
Sites paid
16
Planned or actual enrollment
345

About the trial

Sponsor
Sight Sciences, Inc.
Tested
TearCare System (device), Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion (drug)
Dates
Started 2021-04-28; completion 2024-09-23
Results posted
Yes

To demonstrate the safety and effectiveness of TearCare® procedures compared to Restasis® to treat the signs and symptoms of dry eye disease in adult patients.

From ClinicalTrials.gov, last updated 2025-11-24. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sight Sciences, Inc. reported $219,026 in research payments for this study in 2025 (20 payments).

Products named: Tearcare System

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Mrb Eye Consultants $35,434
  • Moyes Eye Center PC $29,263
  • Gordon Schanzlin New Vision Institute $27,067
  • Wyse Eyecare $23,699
  • Kannarr Eye Care LLC $19,185
  • Pnv Clinical Research LLC $16,246
  • Cleveland Eye Clinic $15,762
  • Eye Research Foundation Inc. $9,905
  • Holpro Vision Ltd $8,968
  • Scripps Health $8,339
  • Rex Aaron Werner Od Inc $6,862
  • Jackson Eye Sc $5,668
  • Ophthalmic PArtners PC $3,865
  • Harvard Eye Associates $3,437
  • $3,205
  • Medical Optometry America $1,267
  • West Bay Eye Associates $858

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.